The Amyloidosis Channel is supported with funding from Prothena (Silver).
The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
BSH 2022 | Unmet needs in amyloidosis treatment in the UK
Ashutosh Wechalekar, MBBS, MD, FRCP, FRCPath, DM, University College London, London, UK, discusses unmet needs in amyloidosis treatment in the UK. Dr Wechalekar first emphasizes the need for an improved treatment network and early diagnosis in amyloidosis, and further mentions the importance of considering unexplained symptoms in patients with myeloma or monoclonal gammopathy of undetermined significance (MGUS), which may be linked to amyloidosis. This interview took place at the 62nd Annual Scientific Meeting of the British Society for Haematology (BSH) 2022, in Manchester, UK.
Disclosures
Honorarium/Advisory boards/Travel support: Alexion, Janssen, Attralus, GSK, Takeda
